Azenta Reports First Quarter Results for Fiscal 2025, Ended December 31, 2024

, /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the first quarter ended December 31, 2024. The results of B Medical Systems are treated as discontinued operations and reflected in total diluted EPS, following the Company's announcement in the fourth fiscal quarter of 2024 of its intention to pursue a sale. Quarter Ended Dollars in millions, except per share data December 31, September 30, December 31, Change 2024 2024 2023 Prior Qtr Prior Yr. Revenue from Continuing Operations $ 148 $ 151 $ 142 (2) % 4 % Organic growth 4 % Sample Management Solutions $ 81 $ 85 $ 79 (4) % 3 % Multiomics $ 66 $ 66 $ 63 0 % 6 % Diluted EPS Continuing Operations $ (0.21) $ (0.00) $ (0.13) NM (63) % Diluted EPS Total $ (0.29) $ (0.10) $ (0.28) NM (5) % Non-GAAP Diluted EPS Continuing Operations $ 0.08 $ 0.22 $ 0.08 (64) % (1) % Adjusted EBITDA - Continuing Operations $ 13 $ 18 $ 7 (25) % 89 % Adjusted EBITDA Margin - Continuing Operations 9.0 % 11.8 % 5.0 % Management Comments"Our first quarter results represent a strong start to fiscal 2025 as we see positive momentum in the demand for our unique offering of Sample Management Solutions and Multiomics services," stated John Marotta, President and CEO. "Starting the year like this gives us confidence in the strength of our unique market positioning, value proposition and ability to continue evolving to our customers' needs while delivering profitable growth. We continue to see the benefit of our transformation initiatives and our free cash flow was strong. We are encouraged by the progress we are making." First Quarter Fiscal 2025 Results - Continuing Operations Revenue was $148 million, up 4% year over year. Organic revenue, which excludes a nominal impact from foreign exchange, was also up 4% year over year. The year-over-year revenue increase was attributable to higher Multiomics and Sample Management Solutions revenues. Sample Management Solutions revenue was $81 million, up 3% year over year. Organic revenue grew 2%, mainly driven by higher revenues in Sample Repository Solutions and Core Products, particularly in Consumables and Instruments and Clinical and Cryogenic Stores Systems. Multiomics revenue was $66 million, up 6% year over year. Organic revenue also grew 6% year over year, primarily driven by growth in Next Generation Sequencing and Gene Synthesis, partially offset by a year-over-year decline in Sanger Sequencing. Summary of GAAP Earnings Results - Continuing Operations Operating loss was $11 million. Operating margin was (7.7%), up 380 basis points year over year. Gross margin was 46.6%, up 300 basis points year over year, driven by higher revenue, favorable sales mix, operational efficiencies, lower amortization costs, and certain non-recurring items recorded in the same period last year. Operating expenses were $80 million, up 3% year over year, driven by higher selling, general and administrative expenses, partially offset by lower research and development costs, as well as lower restructuring charges. Other income included $4 million of net interest income versus $10 million in the prior year period. Diluted EPS from continuing operations was ($0.21) compared to ($0.13) in the first quarter of fiscal year 2024. Diluted EPS from discontinued operations was ($0.09). Total diluted EPS was ($0.29), compared to ($0.28) a year ago. Summary of Non-GAAP Earnings Results - Continuing Operations Adjusted operating loss was $0.2 million. Adjusted operating margin was (0.2%), an improvement of 260 basis points year over year. Adjusted gross margin was 47.6%, up 270 basis points compared to the first quarter of fiscal 2024, primarily driven by higher revenue, favorable sales mix, operating efficiencies and certain non-recurring items recorded in the same period last year. Adjusted operating expense in the quarter was $70 million, up 4% year over year, primarily driven by higher selling, general and administrative expenses, partially offset by lower research and development costs. Adjusted EBITDA was $13 million, and Adjusted EBITDA margin was 9.0%, an improvement of 400 basis points year over year. Non-GAAP Diluted EPS was $0.08, compared to $0.08 one year ago. Cash and Liquidity as of December 31, 2024 The Company ended the quarter with a total balance of cash, cash equivalents, restricted cash and marketable securities of $530 million, which includes $27 million of cash held in discontinued operations. Operating cash flow was $30 million in the quarter. Capital expenditures were $8 million, and free cash flow (cash flow from operations less capital expenditures) was $22 million. Guidance for Continuing Operations for Full Year Fiscal 2025 The Company is reiterating its revenue guidance for fiscal year 2025: Total organic revenue is expected to grow in the range of 3% to 5% relative to fiscal 2024. Adjusted EBITDA margin expansion is expected to be approximately 300 basis points relative to fiscal 2024. Azenta does not provide forward-looking guidance on a GAAP basis for the measures on which it provides forward-looking non-GAAP guidance as the Company is unable to provide a quantitative reconciliation of forward-looking non-GAAP measures to the most directly comparable forward-looking GAAP measure, without unreasonable effort, because of the inherent difficulty in accurately forecasting the occurrence and financial impact of the various adjusting items necessary for such reconciliations that have not yet occurred, are dependent on various factors, are out of the company's control, or cannot be reasonably predicted. Such adjustments include, but are not limited to, transformation costs, restructuring charges, costs related to acquisitions and divestitures costs, governance-related matters, goodwill and intangible impairments, and other gains and charges that are not representative of the normal operations of the business. Conference Call and WebcastAzenta management will webcast its first quarter fiscal 2025 earnings conference call today at 8:30 a.m. Eastern Time. During the call, Company management will respond to questions concerning, but not limited to, the Company's financial performance, business conditions and industry outlook. Management's responses could contain information that has not been previously disclosed. The call will be broadcast live over the Internet and, together with presentation materials referenced on the call, will be hosted at the Investor Relations section of Azenta's website at https://investors.azenta.com/events and will be archived online on this website for convenient on-demand replay. Regulation G – Use of Non-GAAP financial MeasuresThe Company supplements its GAAP financial measures with certain non-GAAP financial measures to provide investors a better perspective on the results of business operations, which the Company believes is more comparable to the similar analyses provided by its peers. These measures are not presented in accordance with, nor are they a substitute for, U.S. generally accepted accounting principles, or GAAP. These measures should always be considered in conjunction with appropriate GAAP measures. A reconciliation of non-GAAP measures to the most nearly comparable GAAP measures is included at the end of this release following the consolidated balance sheets and statements of operations. Certain amounts in the tables that supplement the consolidated financial statements may not sum due to rounding. All percentages are calculated using unrounded amounts. "Safe Harbor Statement" under Section 21E of the Securities Exchange Act of 1934Some statements in this release are forward-looking statements made under Section 21E of the Securities Exchange Act of 1934. These statements are neither promises nor guarantees but involve risks and uncertainties, both known and unknown, that could cause Azenta's financial and business results to differ materially from our expectations. They are based on the facts known to management at the time they are made. Forward-looking statements include but are not limited to statements about our revenue and earnings expectations, our ability to realize margin improvement from cost reductions, and our ability to deliver financial success in the future and otherwise related to future operating or financial performance and opportunities. Factors that could cause results to differ from our expectations include the following: our ability to reduce costs effectively; the volatility of the life sciences markets the Company serves; our possible inability to meet demand for our products due to difficulties in obtaining components and materials from our suppliers in required quantities and of required quality; the inability of customers to make payments to us when due; price competition; disputes concerning intellectual property; uncertainties in global political and economic conditions; and other factors and other risks, including those that we have described in our filings with the Securities and Exchange Commission, including but not limited to our Annual Report on Form 10-K, Current Reports on Form 8-K and our Quarterly Reports on Form 10-Q. As a result, we can provide no assurance that our future results will not be materially different from those projected. Azenta expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statement to reflect any change in our expectations or any change in events, conditions, or circumstance on which any such statement is based. Azenta undertakes no obligation to update the information contained in this press release. About Azenta Life SciencesAzenta, Inc. (Nasdaq: AZTA) is a leading provider of life sciences solutions worldwide, enabling impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and multiomics services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. Our global team delivers and supports these products and services through our industry-leading brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, and Barkey. Azenta is headquartered in Burlington, Massachusetts, with operations in North America, Europe, and Asia. For more information, please visit www.azenta.com. AZENTA INVESTOR CONTACTS: Yvonne PerronVice President, Financial Planning & Analysis and Investor Relations[email protected] Sherry Dinsmore[email protected] AZENTA, INC.CONSOLIDATED STATEMENTS OF OPERATIONS(unaudited) (In thousands, except per share data) Three Months Ended December 31, 2024 2023 Revenue Products $ 43,827 $ 43,707 Services 103,683 98,018 Total revenue 147,510 141,725 Cost of revenue Products 25,334 26,783 Services 53,505 53,199 Total cost of revenue 78,839 79,982 Gross profit 68,671 61,743 Operating expenses Research and development 6,380 7,313 Selling, general and administrative 73,213 69,889 Restructuring charges 431 786 Total operating expenses 80,024 77,988 Operating loss (11,353) (16,245) Other income Interest income, net 4,298 9,955 Other income, net 1,203 518 Loss before income taxes (5,852) (5,772) Income tax expense 3,569 1,420 Loss from continuing operations (9,421) (7,192) Loss from discontinued operations, net of tax (3,919) (8,532) Net loss $ (13,340) $ (15,724) Basic net loss per share: Loss from continuing operations $ (0.21) $ (0.13) Loss from discontinued operations, net of tax (0.09) (0.15) Basic net loss per share $ (0.29) $ (0.28) Diluted net loss per share: Loss from continuing operations $ (0.21) $ (0.13) Loss from discontinued operations, net of tax (0.09) (0.15) Diluted net loss per share $ (0.29) $ (0.28) Weighted average shares used in computing net loss per share: Basic 45,626 56,709 Diluted 45,626 56,709 AZENTA, INC.CONSOLIDATED BALANCE SHEETS(unaudited)(In thousands, except share and per share data) December 31, September 30, 2024 2024 Assets Current assets Cash and cash equivalents $ 377,494 $ 280,030 Short-term marketable securities 85,951 151,162 Accounts receivable, net of allowance for expected credit losses ($5,182 and $5,349, respectively) 155,038 156,273 Inventories 81,006 78,923 Short-term restricted cash 2,080 2,069 Prepaid expenses and other current assets 72,140 75,456 Current assets held for sale 72,573 88,894 Total current assets 846,282 832,807 Property, plant and equipment, net 149,666 155,622 Long-term marketable securities 29,533 49,454 Long-term deferred tax assets 627 837 Operating lease right-of-use assets 60,460 60,406 Goodwill 672,906 691,409 Intangible assets, net 115,822 125,042 Other assets 7,310 10,670 Noncurrent assets held for sale 158,604 173,794 Total assets $ 2,041,210 $ 2,100,041 Liabilities and stockholders' equity Current liabilities Accounts payable $ 31,740 $ 33,344 Deferred revenue 41,018 30,493 Accrued warranty and retrofit costs 4,973 5,213 Accrued compensation and benefits 28,405 27,785 Accrued customer deposits 26,833 22,324 Accrued income taxes payable 6,931 9,266 Accrued expenses and other current liabilities 38,965 46,364 Current liabilities held for sale 23,602 30,050 Total current liabilities 202,467 204,839 Long-term tax reserves 408 398 Long-term deferred tax liabilities 18,668 18,084 Long-term operating lease liabilities 54,341 56,683 Other long-term liabilities 8,229 8,874 Noncurrent liabilities held for sale 38,131 42,196 Total liabilities 322,244 331,074 Stockholders' equity Preferred stock, $0.01 par value - 1,000,000 shares authorized, no shares issued or outstanding — — Common stock, $0.01 par value - 125,000,000 shares authorized, 59,153,757 shares issued and 45,691,888 shares outstanding at December 31, 2024; 59,031,953 shares issued and 45,570,084 shares outstanding at September 30, 2024 592 590 Additional paid-in capital 511,068 505,958 Accumulated other comprehensive loss (55,237) (13,464) Treasury stock, at cost - 13,461,869 shares at December 31, 2024 and September 30, 2024 (200,956) (200,956) Retained earnings 1,463,499 1,476,839 Total stockholders' equity 1,718,966 1,768,967 Total liabilities and stockholders' equity $ 2,041,210 $ 2,100,041 AZENTA, INC.CONSOLIDATED STATEMENTS OF CASH FLOWS(unaudited)(In thousands) Three Months Ended December 31, 2024 2023 Cash flows from operating activities Net loss $ (13,340) $ (15,724) Adjustments to reconcile net loss to net cash provided by operating activities: Depreciation and amortization 18,100 21,866 Provision for bad debts and inventory reserve 1,470 (121) Stock-based compensation 5,112 3,202 Amortization and accretion on marketable securities (541) (704) Deferred income taxes 457 (7,317) Loss on disposals of property, plant and equipment (8) 266 Changes in operating assets and liabilities: Accounts receivable 4,850 2,830 Inventories (4,646) 4,929 Accounts payable (2,602) 2,442 Deferred revenue 10,462 (321) Accrued warranty and retrofit costs 174 (554) Accrued compensation and tax withholdings 650 (979) Accrued restructuring costs (566) (90) Other assets and liabilities 11,056 4,031 Net cash provided by operating activities 30,628 13,756 Cash flows from investing activities Purchases of property, plant and equipment (8,580) (11,291) Purchases of marketable securities (40,754) — Sales and maturities of marketable securities 125,590 110,316 Net cash provided by investing activities 76,256 99,025 Cash flows from financing activities Payments of finance leases (215) (198) Withholding tax payments on net share settlements on equity awards — (2) Share repurchases — (112,953) Excise tax payment for settled share repurchases (4,911) — Net cash used in financing activities (5,126) (113,153) Effects of exchange rate changes on cash, cash equivalents and restricted cash (8,311) 24,548 Net increase in cash, cash equivalents and restricted cash 93,447 24,176 Cash, cash equivalents and restricted cash, beginning of period 320,990 684,045 Cash, cash equivalents and restricted cash, end of period $ 414,437 $ 708,221 Supplemental disclosures: Cash (refund) paid for income taxes, net (6,148) 2,599 Purchases of property, plant and equipment included in accounts payable and accrued expenses 3,249 2,164 Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheets December 31, September 30, 2024 2024 Cash and cash equivalents of continuing operations $ 377,494 $ 280,030 Cash included in current assets held for sale 26,544 30,899 Short-term restricted cash 2,080 2,069 Long-term restricted cash included in other assets 8,319 7,992 Total cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows $ 414,437 $ 320,990 Notes on Non-GAAP Financial Measures - Continuing Operations Non-GAAP financial measures are used in addition to and in conjunction with results presented in accordance with GAAP and should not be relied upon to the exclusion of GAAP financial measures. Management adjusts the GAAP results for the impact of amortization of intangible assets, restructuring charges, purchase price accounting adjustments and charges related to M&A, non-recurring costs related to the Company's business transformation initiatives and share repurchases to provide investors better perspective on the results of operations which the Company believes is more comparable to the similar analysis provided by its peers. Management also excludes special charges and gains, such as impairment losses, gains and losses from the sale of assets, certain tax benefits and charges, as well as other gains and charges that are not representative of the normal operations of the business. Management strongly encourages investors to review our financial statements and publicly filed reports in their entirety and not rely on any single measure. Quarter Ended December 31, 2024 September 30, 2024 December 31, 2023 per diluted per diluted per diluted Amounts in thousands, except per share data $ share $ share $ share Net loss from continuing operations $ (9,421) $ (0.21) $ (88) $ (0.00) $ (7,192) $ (0.13) Adjustments: Amortization of completed technology 1,500 0.03 2,096 0.04 1,856 0.03 Amortization of other intangible assets 4,573 0.10 4,841 0.09 5,371 0.09 Transformation costs(1) 3,046 0.07 4,572 0.09 41 0.00 Restructuring and restructuring related charges 431 0.01 851 0.02 786 0.01 Merger and acquisition costs and costs related to share repurchase(2) 1,570 0.03 53 0.00 4,321 0.08 Tax adjustments(3) 408 0.01 259 0.00 1,693 0.03 Tax effect of adjustments 1,530 0.03 (2,036) (0.04) (2,326) (0.04) Non-GAAP adjusted net income from continuing operations $ 3,637 $ 0.08 $ 10,548 $ 0.20 $ 4,550 $ 0.08 Stock based compensation, pre-tax 4,872 0.11 1,649 0.03 3,001 0.05 Tax rate 15 % — 14 % — 12 % — Stock-based compensation, net of tax 4,141 0.09 1,418 0.03 2,641 0.06 Non-GAAP adjusted net income excluding stock-based compensation - continuing operations $ 7,778 $ 0.17 $ 11,966 $ 0.23 $ 7,191 $ 0.14 Shares used in computing non-GAAP diluted net income per share — 45,626 — 53,175 — 56,709 (1) Transformation costs represent non-recurring expenses for strategic projects with anticipated long-term benefits to the Company focused on cost reduction and productivity improvement that do not meet the definition of restructuring charges. These costs are directed at simplifying, standardizing, streamlining, and optimizing the Company's operations, processes and systems to permanently alter the Company's operations for the long term. For a project to be considered transformational, successful completion of the project must be expected to bring long-term material benefits to the organization and involve significant changes to process and/or underlying technology. Transformation costs in the period result from actions taken as part of the Company's 2024 transformation plan and primarily relate to one time asset write downs associated with changes in technology, one time inventory write downs relating to restructuring actions taken in the period, and third-party consulting costs associated with process and systems re-design. (2) Includes expenses related to governance-related matters. (3) Tax adjustments during all periods include adjustments to tax benefits related to stock compensation. These adjustments are recognized in the period of vesting for US GAAP but included in the annual effective tax rate for Non-GAAP reporting. Quarter Ended December 31, September 30, December 31, Dollars in thousands 2024 2024 2023 GAAP net loss $ (13,340) $ (4,985) $ (15,724) Less: Loss from discontinued operations (3,919) (4,897) (8,532) GAAP net loss from continuing operations (9,421) (88) (7,192) Adjustments: Interest income, net (4,298) (5,532) (9,955) Income tax expense 3,569 2,017 1,420 Depreciation 7,474 7,275 7,420 Amortization of completed technology 1,500 2,096 1,856 Amortization of other intangible assets 4,573 4,841 5,371 Earnings before interest, taxes, depreciation and amortization - Continuing operations $ 3,397 $ 10,609 $ (1,080) Quarter Ended December 31, September 30, December 31, Dollars in thousands 2024 2024 2023 Earnings before interest, taxes, depreciation and amortization - Continuing operations $ 3,397 $ 10,609 $ (1,080) Adjustments: Stock-based compensation 4,872 1,649 3,001 Restructuring charges 431 851 786 Merger and acquisition costs and costs related to share repurchase(1) 1,570 53 4,321 Transformation costs(2) 3,046 4,572 41 Adjusted earnings before interest, taxes, depreciation and amortization - Continuing operations $ 13,316 $ 17,734 $ 7,069 (1) Includes expenses related to governance-related matters. (2) Transformation costs represent non-recurring expenses for strategic projects with anticipated long-term benefits to the Company focused on cost reduction and productivity improvement that do not meet the definition of restructuring charges. These costs are directed at simplifying, standardizing, streamlining, and optimizing the Company's operations, processes and systems to permanently alter the Company's operations for the long term. For a project to be considered transformational, successful completion of the project must be expected to bring long-term material benefits to the organization and involve significant changes to process and/or underlying technology. Transformation costs in the period result from actions taken as part of the Company's 2024 transformation plan and primarily relate to one time asset write downs associated with changes in technology, one time inventory write downs relating to restructuring actions taken in the period, and third-party consulting costs associated with process and systems re-design. Quarter Ended Dollars in thousands December 31, 2024 September 30, 2024 December 31, 2023 GAAP gross profit $ 68,671 46.6 % $ 69,587 46.1 % $ 61,743 43.6 % Adjustments: Amortization of completed technology 1,500 1.0 % 2,096 1.4 % 1,856 1.3 % Transformation costs(1) 52 0.0 % 145 0.1 % — — % Other adjustment 6 0.0 % — — % — — % Non-GAAP adjusted gross profit $ 70,229 47.6 % $ 71,828 47.6 % $ 63,599 44.9 % (1) Transformation costs represent non-recurring expenses for strategic projects with anticipated long-term benefits to the Company focused on cost reduction and productivity improvement that do not meet the definition of restructuring charges. These costs are directed at simplifying, standardizing, streamlining, and optimizing the Company's operations, processes and systems to permanently alter the Company's operations for the long term. For a project to be considered transformational, successful completion of the project must be expected to bring long-term material benefits to the organization and involve significant changes to process and/or underlying technology. Transformation costs in the period result from actions taken as part of the Company's 2024 transformation plan and primarily relate to one time asset write downs associated with changes in technology, one time inventory write downs relating to restructuring actions taken in the period, and third-party consulting costs associated with process and systems re-design. Sample Management Solutions Multiomics Quarter Ended Quarter Ended December 31, September 30, December 31, December 31, September 30, December 31, Dollars in thousands 2024 2024 2023 2024 2024 2023 GAAP gross profit $ 38,114 46.9 % $ 39,543 46.6 % $ 33,272 42.1 % $ 30,557 46.1 % $ 30,044 45.5 % $ 28,471 45.4 % Adjustments: Amortization of completed technology 639 0.8 % 1,056 1.2 % 816 1.0 % 861 1.3 % 1,040 1.6 % 1,039 1.7 % Transformation costs(1) 52 0.1 % 145 0.2 % — — % — — % — — % — — % Other adjustment 5 0.0 % — — % — — % 1 — % — — % — — % Non-GAAP adjusted gross profit $ 38,810 47.8 % $ 40,744 48.0 % $ 34,088 43.1 % $ 31,419 47.4 % $ 31,084 47.1 % $ 29,510 47.1 % Segment Total Quarter Ended December 31, September 30, December 31, Dollars in thousands 2024 2024 2023 GAAP gross profit $ 68,671 46.6 % $ 69,587 46.1 % $ 61,743 43.6 % Adjustments: Amortization of completed technology 1,500 1.0 % 2,096 1.4 % 1,855 1.3 % Transformation costs(1) 52 0.0 % 145 0.1 % — — % Other adjustment 6 0.0 % — — % — — % Non-GAAP adjusted gross profit $ 70,229 47.6 % $ 71,828 47.6 % $ 63,598 44.9 % (1) Transformation costs represent non-recurring expenses for strategic projects with anticipated long-term benefits to the Company focused on cost reduction and productivity improvement that do not meet the definition of restructuring charges. These costs are directed at simplifying, standardizing, streamlining, and optimizing the Company's operations, processes and systems to permanently alter the Company's operations for the long term. For a project to be considered transformational, successful completion of the project must be expected to bring long-term material benefits to the organization and involve significant changes to process and/or underlying technology. Transformation costs in the period result from actions taken as part of the Company's 2024 transformation plan and primarily relate to one time asset write downs associated with changes in technology, one time inventory write downs relating to restructuring actions taken in the period, and third-party consulting costs associated with process and systems re-design. Sample Management Solutions Multiomics Quarter Ended Quarter Ended December 31, September 30, December 31, December 31, September 30, December 31, Dollars in thousands 2024 2024 2023 2024 2024 2023 GAAP operating income (loss) $ 1,562 $ 8,865 $ (1,483) $ (3,387) $ (1,714) $ (4,302) Adjustments: Amortization of completed technology 639 1,056 816 861 1,040 1,039 Amortization of other intangible assets 13 18 51 — — — Transformation costs(1) 103 145 — — — — Restructuring charges — — — 23 — — Rounding adjustment — — — — 1 — Non-GAAP adjusted operating income (loss) $ 2,317 $ 10,084 $ (616) $ (2,503) $ (673) $ (3,263) Total Segments Corporate Total Quarter Ended Quarter Ended Quarter Ended December 31, September 30, December 31, December 31, September 30, December 31, December 31, September 30, December 31, Dollars in thousands 2024 2024 2023 2024 2024 2023 2024 2024 2023 GAAP operating income (loss) $ (1,825) $ 7,151 $ (5,785) $ (9,528) $ (10,148) $ (10,460) $ (11,353) $ (2,997) $ (16,245) Adjustments: Amortization of completed technology 1,500 2,096 1,855 — — 1 1,500 2,096 1,856 Amortization of other intangible assets 13 18 51 4,560 4,823 5,320 4,573 4,841 5,371 Transformation costs(1) 103 145 — 2,943 4,427 41 3,046 4,572 41 Restructuring charges 23 — — 408 851 786 431 851 786 Merger and acquisition costs and costs related to share repurchase(2) — — — 1,570 53 4,321 1,570 53 4,321 Other adjustment — 1 — 9 1 (1) 9 2 (1) Non-GAAP adjusted operating income (loss) $ (186) $ 9,411 $ (3,879) $ (38) $ 7 $ 8 $ (224) $ 9,418 $ (3,871) (1) Transformation costs represent non-recurring expenses for strategic projects with anticipated long-term benefits to the Company focused on cost reduction and productivity improvement that do not meet the definition of restructuring charges. These costs are directed at simplifying, standardizing, streamlining, and optimizing the Company's operations, processes and systems to permanently alter the Company's operations for the long term. For a project to be considered transformational, successful completion of the project must be expected to bring long-term material benefits to the organization and involve significant changes to process and/or underlying technology. Transformation costs in the period result from actions taken as part of the Company's 2024 transformation plan and primarily relate to one time asset write downs associated with changes in technology, one time inventory write downs relating to restructuring actions taken in the period, and third-party consulting costs associated with process and systems re-design. (2) Includes expenses related to governance-related matters. Sample Management Solutions Multiomics Azenta Total Quarter Ended Quarter Ended Quarter Ended December 31, December 31, December 31, December 31, December 31, December 31, Dollars in millions 2024 2023 Change 2024 2023 Change 2024 2023 Change Revenue $ 81 $ 79 3 % $ 66 $ 63 6 % $ 148 $ 142 4 % Currency exchange rates 0 — (1) % 0 — (0) % 0 — (0) % Organic revenue $ 81 $ 79 2 % $ 66 $ 63 6 % $ 147 $ 142 4 % SOURCE Azenta WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Azenta Reports First Quarter Results for Fiscal 2025, Ended December 31, 2024

FAQ

Why Bullish?

How important is it?

Why Short Term?

Related Companies

Related News